Popular Articles

Aditya Birla Nuvo in talks with global PE investors
Aditya Birla Nuvo is in talks with global private equity players Blackstone, Carlyle and KKR to sell shareholding in its proposed holding firm for its financial services business. The financial services holding company will house its asset management, insurance, stock broking, wealth management and private equity businesses.

HCL Infosystem profit falls 11% at Rs 59 cr
HCL Infosystems has seen its profit fall 10.77 per cent. The company has reported a profit of Rs 58.97 crore in the second quarter this financial year as compared to Rs 66.09 crore in the corresponding quarter last financial year.

News of the day

Bank of Maharashtra net down 7%
Public sector lender Bank of Maharashtra reported a 7 per cent drop in net profit to Rs 112 crore for the quarter ended December 2009 against Rs 120.6 crore in the year-ago quarter. Net interest income, or the difference between interest earned and interest paid, grew 5 per cent to Rs 361 crore from Rs 343 crore in the December 2008 quarter.
Online Business

Few takers for govt offer on H1N1 vaccine trials

The central government’s invitation to global pharmaceutical companies to conduct clinical trials here of their H1N1 (swine flu) vaccine candidates has evoked only a limited response. Only two companies, Novartis and GlaxoSmithKline, have come forward to seek regulatory approval for such trials in India, it is learnt. - Natco Pharma launches anti-swine flu drug, Natflu - Obama announces plan to expand fight against swine flu - H1N1 drug trial talks next week - 5 more swine flue deaths, 480 outlets to sell Tamiflu - Tamiflu to be available in market - Govt working to ease mask shortage Industry sources said this was due to the government’s reluctance to place advance orders with the vaccine makers, to purchase their vaccine as and when it is ready. Multinational firms Baxter and Sanofi Pasteur are also in various stages of clinical trials to develop the H1N1 vaccine. Several countries have placed advance orders with these drug majors. Incidentally, Sanofi Pasteur, the vaccine division of Sanofi Aventis, said today its H1N1 vaccine had received US regulatory approval. Health ministry officials said the absence of applications to conduct clinical trials could be considered as lack of interest. “Only two of them have applied. Others might do so in the coming weeks. We are also looking forward to Indian companies to come up with their vaccines,” a senior official said. He added multinational firms with clinical trial approvals could be ready with their vaccines by December. “Indian companies should be ready by April. We don’t see the need to give advance orders when we have a medicine that is capable of curing the illness. Further, there is no guarantee that the vaccine trials will be successful,” he added. India has so far registered over 200 deaths due to the H1N1 flu. According to official figures, of the 30,118 samples tested for Influenza A H1N1 in government laboratories and 6,588 in private labs across the country till September 15, as many as 21 per cent were found to be positive.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):